Talking Medicines

The next pharma patent cliff is coming. In 2026, major drugs like Xolair, Pomalyst, Opsumit and Januvia face U.S. loss of exclusivity, opening the door to generics and biosimilars. Fierce Pharma breaks down the top 10 at risk. 🔗 hubs.la/Q046X3Sw0 #DrugExlcusivity

Scientific influence doesn’t follow territory maps. The future MSL model will be organized around scientific networks, not geography. New article on how predictive intelligence is reshaping Medical Affairs. hubs.la/Q047mYR50 #MedicalAffairs #MSL #Pharma

GLP-1 therapies are expanding beyond diabetes into cardiovascular, kidney, and inflammatory care. New evidence highlights broader metabolic and anti-inflammatory benefits, driving more integrated patient care discussions. Read more from TMLabs👉 talkingmedicines.com/2026/03/the-ex… #GLP1s

Medical Affairs has measured activity for decades. But activity doesn’t show which scientific messages actually change HCP behavior. Our latest blog explores how predictive intelligence and Message Resonance Score™ reveal what truly resonates. hubs.la/Q047mst80

Bristol Myers Squibb secures an FDA expansion for Sotyktu in psoriatic arthritis. Another signal of how immunology competition is accelerating and why understanding real HCP message resonance matters more than ever. hubs.la/Q0468DvV0 #PsoriaticArthritis #Immunology #FDA

New from TMLabs: exploring why ethical AI and responsible health data will shape the future of healthcare. Read the full blog here 👇hubs.la/Q046zdW20

Pharma clients want proof that strategy moves HCP behavior, not just engagement. Our latest article explores how Agencies use Message Resonance Score™ to evidence real impact and build predictable ROI. Read more in our blog:hubs.la/Q0468xS70 #PredictableROI

As DTC and DTP strategies evolve, pharma is turning to podcasts to harness the power of storytelling to build consumer trust. For Agencies, the question is no longer just reach. It is resonance. How are you evidencing impact across consumer channels? hubs.ly/Q0457qsv0

Rare diseases such as spinal muscular atrophy (SMA) are caused by mutations in specific genes, often leading to progressive symptoms. Advances in gene therapy are exploring ways to target the underlying genetic cause of these conditions. hubs.la/Q045KHlx0 #RareDiseases

Pharma consumerism is changing how HCPs and Patients engage and decide. In 2026, commercial strategy must reflect real expectations and behaviors. What does consumerism in Pharma really mean? Read more: hubs.la/Q044ZlLr0 #Pharma #MedComms

What does it really mean to be an AI agency in Life Sciences? In PM360, Faruk Capan of EVERSANA INTOUCH argues it is not about tools, but governance, integration, and measurable impact. A sharp take on moving beyond AI as a label. hubs.la/Q044NrVM0

What if your HCP personas did more than align teams? Learn how personas built from real HCP voice and validated through measurable resonance become predictive strategic tools that strengthen messaging and drive behavioral impact. Read more: hubs.la/Q044ZnLw0

Scotland’s strength in AI has been decades in the making, especially across healthcare, modelling, and data science. That ecosystem is exactly why TMLabs is proud to be part of Scotland’s growing innovation hub. Read the full blog here:hubs.la/Q042PWkq0

Two months into 2026 and the AI conversation has shifted. It’s no longer “should we adopt AI?” It’s “what kind of AI delivers value?” In Life Sciences, generic tools create speed. Purpose-built AI creates intelligence you can measure and defend. hubs.la/Q042PMvj0

Precision medicine is reshaping treatment development. Precision marketing must evolve how therapies are activated. In @PM360online, Dana Smith explains how data and AI enable more relevant, outcome focused engagement with HCPs and Patients. pm360online.com/expert-on-call…

Precision medicine is moving beyond one dose fits all. Genetics cannot fully explain variable drug response. Bioavailability and the gut microbiome also shape how therapies are absorbed and experienced. Explore why this matters for drug development: hubs.la/Q043_GPD0

Great piece from Carolyn Stephenson (Syneos Health) on why human-centred AI is key to more evidence-based Pharma marketing. With DrugVoice, we see the same shift: continuous intelligence over snapshots. Worth a read: hubs.la/Q042Q6V70

In Life Sciences, impact is not driven by the loudest launch. It is driven by relevance at the moments that shape clinical decisions. Therapy positioning must align with how disease unfolds in the real world, from diagnosis through long-term follow-up. hubs.la/Q042QpsN0

The GLP-1 story keeps changing, and so does what HCPs and Patients expect from these treatments. Understanding real-life interpretation is now the strategic advantage. hubs.la/Q042thGL0 #GLP1 #MessageResonance #HCPAnalytics

We’re proud to celebrate the incredible women at Talking Medicines, including the brilliant minds behind TMLabs, by sharing the moment they first felt like they truly belonged in science. Because representation matters. And so do the voices shaping the future of Life Sciences.